Skip to main content
. Author manuscript; available in PMC: 2013 Sep 30.
Published in final edited form as: AIDS. 2013 Apr 24;27(7):1045–1057. doi: 10.1097/QAD.0b013e32835cffd9

Fig. 4. Phylogenetic insights on future possibilities in HIV prevention.

Fig. 4

Temporal expansion of small (2–4 PHI) and large (5–60) clusters are denoted by solid and dashed lines, respectively. Testing must be frequent to capture individuals in a timely fashion for ‘Treatment for as Prevention’ (TasP) paradigms. Antiretroviral drug (ART) pharmacokinetics and patient adherence to ART is necessary to prevent viral bound and chronic stage transmissions.